Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07566091
NA

Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers

Sponsor: Jung-min Ahn

View on ClinicalTrials.gov

Summary

The objective of this study is to demonstrate the primary hypothesis that, in patients with chronic and acute coronary syndromes requiring percutaneous coronary intervention (PCI), the novel sirolimus-ascorbic acid eluting stent (D+Storm Novonix) is non-inferior to the standard treatment, the everolimus-eluting stent (Synergy XD), with respect to the incidence of target lesion failure (TLF) at 1 year after treatment, where TLF is defined as a composite of cardiovascular death, target vessel myocardial infarction, and clinically driven target-lesion revascularization.

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

2034

Start Date

2026-10-15

Completion Date

2028-06-15

Last Updated

2026-09-23

Healthy Volunteers

No

Interventions

DEVICE

Sirolimus-Ascorbic Acid Eluting Stent

bioabsorbable polymer Sirolimus-Ascorbic Acid Eluting Stent

DEVICE

Everolimus-Eluting Stent

bioabsorbable polymer everolimus-eluting stent

Locations (1)

Asan Medical Center

Seoul, South Korea